Rapport Therapeutics (RAPP) Net Equity Issued and Repurchased (2024)
Rapport Therapeutics (RAPP) posted quarterly Net Equity Issued and Repurchased of -$87000.0 for Q2 2024, down 100.14% quarter-over-quarter from $64.0 million in Q1 2024.
Powered by 
Analysis
Rapport Therapeutics (RAPP) Net Equity Issued and Repurchased (2024) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Net Equity Issued and Repurchased for 2 consecutive years, with -$87000.0 the latest figure, recorded in Q2 2024.
- In Q2 2024, Net Equity Issued and Repurchased changed N/A year-over-year to -$87000.0; the TTM figure through Dec 2024 stood at $63.9 million (changed N/A YoY), while the FY2024 annual figure was $63.9 million, changed 0.0% from the prior year.
- Net Equity Issued and Repurchased declined to -$87000.0 in Q2 2024 per RAPP's latest filing, from $64.0 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $64.0 million in Q1 2024 and bottomed at -$87000.0 in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 141.90 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Rapport Therapeutics | 2.17 Bn | 2.17 Bn | - | - |